Seoul

Running trials

• Active, not recruiting

  An Observational Prospective Long-term Exposure Registry of Adult Patients With Moderate-to-Severe Ulcerative Colitis

  NCT02808780· Source

• Active, not recruiting

  Study of Amivantamab, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung Cancer

  NCT02609776· Phase 1· Source

• Active, not recruiting

  A Study of Apalutamide (JNJ-56021927, ARN-509) Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With mHSPC

  NCT02489318· Phase 3· Source

• Active, not recruiting

  An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS

  NCT02531516· Phase 3· Source

• Active, not recruiting

  A Study of Two Different Doses of Cabozantinib (XL184) in Progressive, Metastatic Medullary Thyroid Cancer

  NCT01896479· Phase 4· Source

• Active, not recruiting

  An Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)

  NCT02257736· Phase 3· Source

• Active, not recruiting

  A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate Cancer

  NCT01946204· Phase 3· Source

• Active, not recruiting

  A Long-term Extension Study of PCI-32765 (Ibrutinib)

  NCT01804686· Phase 3· Source

• Recruiting

  Product Surveillance Registry

  NCT01524276· Source

• Active, not recruiting

  Psoriasis Longitudinal Assessment and Registry

  NCT00508547· Source

• Recruiting

  Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products

  NCT00271180· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Coronary artery disease1 recruiting
• Heart failure1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  A Study to Evaluate the Clinical Efficacy of JNJ-42756493 (Erdafitinib), A Pan-Fibroblast Growth Factor Receptor (FGFR) Tyrosine Kinase Inhibitor, In Asian Participants With Advanced Non-Small-Cell Lung Cancer, Urothelial Cancer, Esophageal Cancer Or Cholangiocarcinoma

  NCT02699606· Phase 2· Source

• Completed

  A Long-term Extension Study of Riociguat in Patients With Symptomatic Pulmonary Arterial Hypertension.

  NCT02759419· Phase 4· Source

• Completed

  A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma

  NCT02195479· Phase 3· Source

• Completed

  Addition of Daratumumab to Combination of Bortezomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma

  NCT02136134· Phase 3· Source

• Completed

  A Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma

  NCT02076009· Phase 3· Source

• Completed

  A Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib Given in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma

  NCT01776840· Phase 3· Source

• Completed

  A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma

  NCT01712490· Phase 3· Source